Despite a double improvement and a slightly more favourable rating at Neutral, NEVRO remains unattractive
NEVRO (US), a company active in the Medical Equipment industry, has received a double requalification by the independent financial analyst theScreener. Its fundamental valuation now shows 1 out of 4 stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) and an improvement in the market risk perception allow raising the general evaluation to Neutral. As of the analysis date March 18, 2022, the closing price was USD 70.61 and its target price was estimated at USD 50.19.Nevro is a medical device company that has developed and commercialized the Senza? spinal cord stimulation, a neuromodulation platform for the treatment of chronic pain. The Senza system is approved to create electrical impulses from two Hz to 10,000 Hz, including the company's proprietary HF10 therapy, which allows for pain relief without paresthesia. Senza is consisted of leads, a trial stimulator, an implantable pulse generator (IPG), surgical tools, a clinician laptop programmer, a patient remote control and a mobile charger. These components enable physicians to implant the leads and the IPG, and patients to operate the system.
Empowering Investors
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
- Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization. theScreener state of art: We provide
- theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
- For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.